anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Bright Futures control condition consists of standard of care in addressing emotional and behavioral health as provided by pediatricians. Pediatricians will follow the 4th edition of the Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents \[pocket guide\]. Guidelines are provided for topics to discuss and anticipatory guidance at each well-child visit. In contrast to IBH-P, there is an emphasis on didactic presentation, teaching mothers about developmental milestones, and responding to questions and concerns. These include discussions of crying, soothing, and feeding, although self-regulation is not a unifying theme.
IUD's are a tremendously effective long acting, reversible method of contraception, and they require little participation from the woman after insertion. Despite these benefits, few women in the US use an IUD. Education is important so that both providers and women understand that IUD's are safe and effective in women even if they have never had a child. Insertion of an IUD in nulliparous patients can be more difficult and uncomfortable. The purpose of this study is to see if use of misoprostol prior to IUD placement in nulliparous women can make it easier and less painful. The goal is that more information on the feasibility and ease of IUD insertion will make it more accessible to more women. The findings from this trial will be used in a prospective meta analysis on this topic.
PCT No. PCT/SE94/00297 Sec. 371 Date Dec. 21, 1995 Sec. 102(e) Date Dec. 21, 1995 PCT Filed Mar. 31, 1994 PCT Pub. No. WO95/01804 PCT Pub. Date Jan. 19, 1995A pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising recombinant coagulation factor VIII and use thereof for manufacture of a medicament for treating haemophilia is provided. The formulation comprises a highly purified recombinant coagulation factor VIII in a concentration of at least 1000 IU/ml, which gives surprisingly high levels of active factor VIII in the blood stream after subcutaneous, intramuscular or intradermal administration. The formulation is intended for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration. The recombinant factor VIII is preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.
1. Technical Result Reducing of toxic properties.         2. Essence A pharmaceutical composition for oral administration, which as an active agent comprises at least one compound selected among the group consisting of formula (I)    and compound of formula (II)   and is used in medicine for making preparations for treatment of infections caused by different microorganisms.         3. Field of Application Medicine.
The invention relates to a water lily biological wound hemostatic powder. The hemostatic powder is mainly composed of water lily gel, water lily mucus protein, chitosan, pseudo-ginseng powder, (plant hairs) cibotium barometz powder, and polyhexamethylene guanidine according to a certain ratio. The hemostatic powder has the functions of stopping bleeding, relieving pain, and eliminating inflammation. There are many kinds of wound powder with different functions in the market, but the wound powder has certain biological side effects. The invention belongs to the technical field of external application in medicine. The provided hemostatic powder is made of plants and biological substances, thus has a good biocompatibility, and is suitable for various skin wounds. The effects on killing bacteria, eliminating inflammation, and stopping bleeding are good, the water content is high, the tensile strength is high, and moreover, the hemostatic powder is capable of preventing fluid penetration, promoting the generation of granulation tissue and epithelial tissue, and rapidly healing and repairing the skin tissue, has the advantages of good flexibility, expanding property, breathability, and biological safety, excellent product performance, low price, and user-friendliness, can be widely promoted and used, and can be used to stop bleeding, prevent wound inflammation, kill bacteria, disinfect, avoid adhesion, create a fresh and dry environment, and promote skin tissue healing and repairing.
Concomitant coronary artery disease (CAD) is frequent in patients referred for transcatheter aortic valve replacement (TAVI) and there is evidence for a subsequent prognostic impairment. Percutaneous coronary intervention (PCI) is believed to improve prognosis in selected cases, which is why current guidelines recommend PCI to be considered in case of coronary artery diameter stenosis \> 70% in proximal segments. Beyond those cases, selection is hampered by inherent shortcoming of the assessment of CAD severity by angiography alone as well as clinical and complex hemodynamic interactions between both pathologies. In patients with CAD alone, the FDA-cleared near-infrared spectroscopy and intravascular imaging (NIRS-IVUS) dual imaging catheter (Indfraredx, Inc., Bedford, USA) has proven the ability to reliably measure lipid plaque burden as well as to identify patients and plaques at increased risk for future adverse cardiovascular events. NIRS-IVUS imaging offers the unique possibility to improve angiographic CAD severity assessment in patients referred for TAVI, avoiding the influence of hemodynamic interactions and pathophysiological overlap between CAD and severe AS.

The IMPACTavi trial is designed as a prospective, non-randomized cohort study to investigate whether NIRS-IVUS-derived lesion characteristics will allow identification of patients likely to suffer adverse clinical events during clinical follow-up after TAVI. Patients with severe aortic stenosis will be qualified for enrollment if routine coronary angiography during diagnostic workup before TAVI shows evidence of coronary artery disease with at least one native vessel without prior stent implantation and at least one lesion requiring NIRS-IVUS imaging for clinical indications, and if at 30mm of total NIRS-IVUS pullback length in sufficient quality for offline analysis have been obtained. Clinical indication, technique and timing of PCI and TAVI will be at the discretion of the interdisciplinary heart-team. The primary and secondary endpoints will be assessed during clinical follow-up out to 24 months. Findings from NIRS-IVUS imaging will be analyzed on a patient- and lesion-level, in order to evaluate correlations of high- vs. low-risk lesion characteristics to the incidence of patient- and lesion-level MACE.
Sepsis-associated acute liver injury (ALI) is a deadly condition resulting from a systemic inflammatory response to liver cell damage and malfunction. Monotropein (MON) belongs to the iris group of compounds extracted from the natural product Mollen dae officinalis radix, which has strong anti-inflammatory and antioxidant pharmacological effects. The purpose of this study was to elucidate the underlying mechanism of MON in the treatment of sepsis ALI. In this study, an in vivo caecal ligation puncture (CLP)-induced ALI model and in vitro LPS-stimulated AML12 cells and RAW264.7 cells model were established. Additionally, a variety of experimental techniques, including CCK8, H&E staining, DHE probe labelling, biochemical, QPCR, and Western blotting and blocking tests, were used to explore the role of MON in ALI. The results showed that MON improved liver morphological abnormalities, oedema, histopathological injury, and elevated ALT and AST, providing a protective effect against ALI. MON reduced CYP2E1 expression, alleviated oxidative stress (downregulation of MDA levels and upregulation of GSH, CAT, and T-AOC levels) and ROS accumulation with the involvement of the NRF2-Keap-1 pathway. MON inhibited inflammation via the TLR4/NF-κB/NLRP3 inflammasome pathway. In addition, it activated the Akt (Ser473)/GSK3β (Ser9)/Fyn pathway and accelerated NRF2 nuclear accumulation; MK-2206 blockade reversed the NRF2 nuclear accumulation and anti-inflammatory function of MON. MON also restricted the mitochondrial apoptosis pathway, a process specifically blocked by MK-2206. In summary, we concluded that MON alleviated septic ALI by restricting oxidative stress, inflammation, and apoptosis via the AKT (Ser473)/GSK3β (Ser9)/Fyn/NRF2 pathway.
PURPOSE:To obtain a pharmaceutical composition, containing pirenzepines, hardened oil and polyoxyethylene polyoxypropylene copolymer, capable of inhibiting bitterness without deteriorating elution property and useful for gastritis, etc. CONSTITUTION:A pharmaceutical composition obtained by containing pirenzepine expressed by the formula or acid addition salts thereof (e.g. hydrochloride), hardened oil (e.g. hardened castor oil) and polyoxyethylene polyoxypropylene copolymer. Since the compound expressed by the formula which is a principal agent and acid addition salts thereof strong bitterness, preparation of a pharmaceutical with prevented bitterness is required for facilitating administration. The above-mentioned composition suppresses bitterness and has properties of delaying elution of the principal drug. Furthermore, aforementioned copolymer improves the delayed elution by the hardened oil. Since rapid solubility is also required as a medicine for gastritis, etc., a cellulosic water-soluble high polymer is preferably further added.
Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients will receive a total daily dose of 2-4 g/day based on weight-tiered doses.
Colorectal cancer (CRC) is a heterogenous malignancy underpinned by dysregulation of cellular signaling pathways. Previous literature has implicated aberrant JAK/STAT3 signal transduction in the development and progression of solid tumors. In this study we investigate the effectiveness of inhibiting JAK/STAT3 in diverse CRC models, establish in which contexts high pathway expression is prognostic and perform in depth analysis underlying phenotypes. In this study we investigated the use of JAK inhibitors for anti-cancer activity in CRC cell lines, mouse model organoids and patient-derived organoids. Immunohistochemical staining of the TransSCOT clinical trial cohort, and 2 independent large retrospective CRC patient cohorts was performed to assess the prognostic value of JAK/STAT3 expression. We performed mutational profiling, bulk RNASeq and NanoString GeoMx® spatial transcriptomics to unravel the underlying biology of aberrant signaling. Inhibition of signal transduction with JAK1/2 but not JAK2/3 inhibitors reduced cell viability in CRC cell lines, mouse, and patient derived organoids (PDOs). In PDOs, reduced Ki67 expression was observed post-treatment. A highly significant association between high JAK/STAT3 expression within tumor cells and reduced cancer-specific survival in patients with high stromal invasion (TSPhigh) was identified across 3 independent CRC patient cohorts, including the TrasnSCOT clinical trial cohort. Patients with high phosphorylated STAT3 (pSTAT3) within the TSPhigh group had higher influx of CD66b + cells and higher tumoral expression of PDL1. Bulk RNAseq of full section tumors showed enrichment of NFκB signaling and hypoxia in these cases. Spatial deconvolution through GeoMx® demonstrated higher expression of checkpoint and hypoxia-associated genes in the tumor (pan-cytokeratin positive) regions, and reduced lymphocyte receptor signaling in the TME (pan-cytokeratin- and αSMA-) and αSMA (pan-cytokeratin- and αSMA +) areas. Non-classical fibroblast signatures were detected across αSMA + regions in cases with high pSTAT3. Therefore, in this study we have shown that inhibition of JAK/STAT3 represents a promising therapeutic strategy for patients with stromal-rich CRC tumors. High expression of JAK/STAT3 proteins within both tumor and stromal cells predicts poor outcomes in CRC, and aberrant signaling is associated with distinct spatially-dependant differential gene expression.
The invention discloses an oxacyclononano [4,5-b ] indole structure and a synthesis method and application thereof. The invention provides an oxacyclononano [4,5-b ] indole structure. The invention provides a synthesis method thereof, which comprises the following steps: uniformly mixing a quaternary synthon containing an oxindole skeleton and 1,2-di (bromomethyl) benzene in a solvent, reacting at 50-90 ℃ under an alkaline condition, adding lithium aluminum hydride into the reaction mixture to continue reacting, extracting the mixture after reacting, adding the organic phase after extracting and concentrating into silica gel to react in the solvent, and preparing the oxacyclononane [4,5-b ] indole compound. The invention provides a pharmaceutical composition. The invention also provides application of the oxacyclononane [4,5-b ] indole skeleton in preparation of medicines for treating cancers and the like. The method for efficiently synthesizing the oxacyclononane [4,5-b ] indole compound provided by the invention realizes the efficient construction of an oxacyclononane [4,5-b ] indole skeleton for the first time through a [4+4] cyclization/ring expansion tandem reaction.
PURPOSE:To obtain toilet lotion having high moisture-retaining effect only by adding a small amount of a betaine having excellent moisture-retaining action and touch-improving action, giving extremely good feeling after use by including the betaine as an active ingredient. CONSTITUTION:This toilet lotion contains a betaine expressed by the formula (another name: trimethyl glycine, glycine betaine or alkyl dimethylbetaine) as an active ingredient. The betaine expressed by the formula is blended in an amount of 0.05-20 pts.wt., preferably 2-5 pts.wt. in the toilet lotion. The toilet lotion can contain a solvent such as ethanol, a softening agent such as ester oil, a solubilizing agent such as polyoxyethylene oil alcohol ester, a thickening agent such as alginic acid, a perfume such as geraniol, a preservative such as methyl paraben, a humectant such as glycerol, etc., in addition to the essential ingredient. The toilet lotion is free from stickiness and excellent in moistening feeling and slippery feeling.
PROBLEM TO BE SOLVED: To obtain a hair tonic cosmetic stable over time by its pH adjustment. SOLUTION: This hair tonic cosmetic is obtained by removing pilocarpine from the extract from the leaves of pilocarpus, a kind of rutaceous plant (e.g. pilocarpus jaborandi, pilocarpus microphyllus), and adjusting the pH level of the resultant extract to >=2 but <7. The amount of the active ingredient of this cosmetic to be formulated is pref. 0.005-10wt.% (in terms of dry weight) based on the whole amount of the cosmetic. The pH adjuster to be used is e.g. an alkaline substance such as an alkali (alkaline earth) metal hydroxide. The extraction is preferably carried out at 10-100 deg.C for one hour to 10 days by use of 5-100 pts.wt. of a solvent (e.g. water, ethanol) per pt.wt. of the dry leaves.  Besides, it is preferable that this cosmetic be formulated with a germicide such as benzoic or salicylic acid because of possible decline in its antimicrobial potency depending on its pH level.
Participants who do not engage in the Tele-CABA intervention during their time in the study. They will be eligible to receive Tele-CABA following completion of the 6-month questionnaires and cognitive assessment (as a courtesy).
FIELD: medicine, cosmetology. SUBSTANCE: the present innovation deals with manufacturing curative-prophylactic hygienic antiherpetic preparations. The suggested preparation contains trisodium salt of phosphonformic acid as an antiherpetic ingredient at the quantity of 0.1-3 weight% and, additionally, at least, one cosmetically acceptable saturated dicarbonic acid at the quantity of 0.05-0.2 weight% for example, glutaric and adipic acids, and, also, any cosmetically acceptable foundation containing predominantly methyl and propyl esters of paraoxybenzoic acid in efficient quantities as conservants, and as emulsifier - dipolyhydroxystearate and/or laurylmeticon copolyol, as emolent - caprylic triglycerides and/or isohexane and/or dimeticon, as a lipid carrier - vegetable oils. Preparation suggested can, also, contain biologically active, medicinal, aromatizing, dyeing additives, for example, bee wax, betaine, Trilon-B, citric acid. The preparation is of antiherpetic activity and is recommended to be applied as prophylactic antiherpetic balsam for lips. EFFECT: higher efficiency. 16 cl, 2 ex
Researchers at the University of North Carolina at Greensboro are conducting a single-arm intervention trial to investigate the efficacy of a music-based group exercise program for community-dwelling older adults. Up to forty participants will be recruited to participate in a music-based light-to-moderate intensity group exercise program for 20 weeks (30 - 40 min/day, up to 6 days/week), which is designed for older adults with or without functional limitations to exercise with chairs for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace. During the exercise sessions, participants will be trained to move in time with music playlists in synchronous tempos. Primary outcomes are cognitive performance, mobility, and health-related quality of life measured before and after the intervention. Secondary outcomes are adherence to the exercise program as a potential mediator of the treatment. The research team aims to determine whether (1) a music-based light-to-moderate intensity group exercise intervention beneficially impacts mobility, cognitive function, and health-related quality of life in community-dwelling older adults; (2) the treatment effect is mediated by adherence to physical activity; and (3) the treatment effect is moderated by cognitive impairment or functional limitations.
Hyponatremia can occur as a result of treatment with carbamazepine extended-release capsules. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The risk of developing SIADH with carbamazepine extended-release capsules treatment may be dose-related. Elderly patients may be at greater risk of developing hyponatremia. Patients treated with diuretics can be at greater risk. Consider discontinuing carbamazepine extended-release capsules in patients with symptomatic hyponatremia. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.
Clinical trials have been conducted with exemestane given as a single dose to healthy female volunteers at doses as high as 800 mg and daily for 12 weeks to postmenopausal women with advanced breast cancer at doses as high as 600 mg. These dosages were well tolerated. There is no specific antidote to overdosage and treatment must be symptomatic. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.

A male child (age unknown) accidentally ingested a 25 mg tablet of exemestane. The initial physical examination was normal, but blood tests performed 1 hour after ingestion indicated leucocytosis (WBC 25,000/mm3 with 90% neutrophils). Blood tests were repeated 4 days after the incident and were normal. No treatment was given.

In mice, mortality was observed after a single oral dose of exemestane of 3,200 mg/kg, the lowest dose tested (about 640 times the recommended human dose on a mg/m2 basis). In rats and dogs, mortality was observed after single oral doses of exemestane of 5,000 mg/kg (about 2,000 times the recommended human dose on a mg/m2 basis) and of 3,000 mg/kg (about 4,000 times the recommended human dose on a mg/m2 basis), respectively.

Convulsions were observed after single doses of exemestane of 400 mg/kg and 3,000 mg/kg in mice and dogs (approximately 80 and 4,000 times the recommended human dose on a mg/m2 basis), respectively.
Participants received ASP8062 tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 dose.
Patients receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or MUGA during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Locally recurrent rectal cancer (LRRC) involving the lateral pelvic sidewall requires a complex approach to maximize the likelihood of R0 resection, which is the only predictor of survival. The purpose of this report is to describe a novel technique to resect a localized lateral pelvic sidewall LRRC. A 63-year-old male patient was referred for a 15-mm LRRC near the right internal iliac vessels. Endoscopic ultrasound and magnetic resonance imaging excluded any involvement of the pelvic colon or residual rectum. A combined extraperitoneal antero-lateral approach and gluteal access were used to optimize vascular control on the internal iliac vessels, to promptly identify the ureter and to achieve a better posterior exposition of the sciatic notch. This technique allowed a controlled and tailored resection of pelvic sidewall without entering into the abdominal cavity. The postoperative course was uneventful. The pathologic report confirmed clear margins (R0), with one involving obturator lymph node. At 3 months, the patient is alive and free from local re-relapse. A right lung metastasis has occurred, and it was treated by stereotactic radiotherapy. The present report proposes a novel extraperitoneal pelvic sidewall excision to resect lateral LRRC with a colorectal-sparing approach, thus minimizing the risk of exenterative surgery-related complications. A proper selection of patients is mandatory, as the proposed technique could not be generalized as the standard of care in all lateral LRRCs.
PURPOSE: In patients with acromegaly, secondary treatment options in cases of hormonal non-remission or tumor progression include repeat transsphenoidal surgery (TSS), radiation-based treatment (RT), or medical therapy (MT). In this study, we aim to evaluate the clinical effectiveness of various second-line treatment options for acromegaly.
METHODS: Using the PRISMA guideline, a systematic review was performed by searching MEDLINE (PubMed), Web of Science, Scopus, and Cochrane electronic bibliographic databases from conception to the end of 2022. Outcomes of interest included hormonal remission rate, complications, and mortality associated with each treatment modality for refractory acromegaly.
RESULTS: A total of 79 studies including 3,208 refractory acromegaly patients (44.90% males) were analyzed, with a mean patient age of 43.89 years. There was a statistically significant difference between various therapeutic modalities in terms of remission rate, with MT offering the highest remission rate (62.55%), followed by RT (50.15%) and TSS (37.39%). Subgroup analysis of radiotherapeutic and medical modalities did not show a significant difference in remission rate between different kinds of sub-modalities in each treatment approach. Recurrence following secondary treatment was not different in patients treated with reoperation TSS compared to other modalities.
CONCLUSIONS: The management of persistent and recurrent acromegaly optimally requires a multimodal approach. In different scenarios of refractory acromegaly based on previous treatment, secondary treatments may vary in terms of remission rate and complications. Medical agents provide considerable effectiveness as a second-line therapy for recurrent or persistent disease. In selected cases, however, reoperation still provides an opportunity for cure or freedom from medications. The findings of this study may help clinicians to prioritize varying options involved in this multifaceted decision-making process.
Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.